Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Nestle proposes new CEO

This article was originally published in The Tan Sheet

Executive Summary

Nestle's board of directors proposes Paul Bulcke, a member of Nestle's executive board and head of Zone Americas, take on the role of CEO at the firm's next annual board meeting April 10, 2008. Current CEO Peter Brabeck-Letmathe will serve as active, non-executive, chairman, Nestle said Sept. 20. The board cites the decision to separate the chairman and CEO positions, anticipating an increasing workload for the chairman's office, and the desire for management continuity by entrusting the CEO position to a younger person as reasons for appointing Bulcke. Bulcke's nomination took place under the leadership of the independent Compensation and Nomination Committee and was received unanimous approval by the board. Bulcke's successor at Zone Americas will be announced Oct. 18...

You may also be interested in...



Nestle sales

"Robust innovation and renovation pipeline" for infant formula contributed to 6.6% growth in Nestle Nutrition sales to 5.7 bil. Swiss Francs ($4.87 bil.) for the January-September period, company announces Oct. 18. For the nine-month period, organic sales advanced 9.7%, "in line with the business' long-term target of 10%," firm adds. "NAN premium starter formulas and Nestle infant cereals enriched with probiotics to strengthen infants' immune systems, did particularly well in their global rollout," according to Nestle. Firm's Powdered and Liquid Beverages unit achieved sales of 12.8 bil. Swiss Francs ($10.9 bil.), representing growth of 7.5%, or 10% organically. Nestle also announces promotion of Acquisitions and Business Development Chief Jim Singh to CFO, and Paul Polman as head of Zone Americas, replacing Paul Bulcke, who will assume the CEO post in the spring (1"The Tan Sheet" Oct. 1, 2007, In Brief)...

US Election 2020: Device Firms Spending Twice As Much On Biden Than On Trump

Just five weeks before the US election, a Medtech Insight analysis shows medical device companies are spending more on Democrat Joe Biden’s campaign than on Republican Donald Trump’s.

Orphazyme Raises Funds, Approaching Markets With Novel Niemann-Pick Therapy

Denmark’s Orphazyme has raised more funds to market its lead product, the heat shock protein amplifier, arimoclomol, in the US and Europe, and to evaluate the compound for other lysosomal storage and neurodegenerative disorders.

Topics

UsernamePublicRestriction

Register

ID1132115

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel